Market Exclusive

Foundation Medicine, Inc. (NASDAQ:FMI) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Foundation Medicine, Inc. (NASDAQ:FMI) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On April 11, 2017, Dr. David Schenkein, M.D. informed the Board of Directors (the “Board”) of Foundation Medicine, Inc. (the “Company”) of his intention not to stand for re-election to the Board at the Company’s 2017 Annual Meeting of Stockholders (the “Annual Meeting”), and to retire from the Board effective as of the date of the Annual Meeting. Dr. Schenkein currently serves as a member of the Audit Committee of the Board. Dr. Schenkein’s decision not to stand for re-election to the Board was not a result of any disagreement with the Company or the Board.

About Foundation Medicine, Inc. (NASDAQ:FMI)
Foundation Medicine, Inc. is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. The Company’s segment is the business of delivering molecular information about cancer to its customers. Its products provide genomic information about each patient’s individual cancer, enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted oncology therapies. Its flagship clinical molecular information products, FoundationOne for solid tumors, and FoundationOne Heme for blood-based cancers or hematologic malignancies, including leukemia, lymphoma, myeloma and advanced sarcomas, are genomic profiles designed for use in the routine care of patients with cancer. Its other products include FoundationACT (Assay for Circulating Tumor deoxyribonucleic acid (DNA)), GeneKit, FoundationCORE, FoundationICE and the SmartTrials program. Foundation Medicine, Inc. (NASDAQ:FMI) Recent Trading Information
Foundation Medicine, Inc. (NASDAQ:FMI) closed its last trading session up +0.90 at 31.35 with 154,076 shares trading hands.

Exit mobile version